Amplia Therapeutics Limited (ATX.AX)
AUD 0.05
(-1.89%)
AUD 0.05
(-1.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 4.01 Million AUD | 259.35% |
| 2023 | 1.11 Million AUD | -43.63% |
| 2022 | 1.98 Million AUD | 29.18% |
| 2021 | 1.53 Million AUD | 4485.93% |
| 2020 | 33.42 Thousand AUD | -31.62% |
| 2019 | 48.88 Thousand AUD | -91.27% |
| 2018 | 560.12 Thousand AUD | -68.2% |
| 2017 | 1.76 Million AUD | 3.91% |
| 2016 | 1.69 Million AUD | 916.11% |
| 2015 | -207.68 Thousand AUD | -24.15% |
| 2014 | -167.28 Thousand AUD | 29.28% |
| 2013 | -236.52 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | 4.36 Million AUD | 291.23% |
| 2024 Q2 | 2.4 Million AUD | 0.0% |
| 2024 Q4 | 1.67 Million AUD | 0.0% |
| 2023 Q4 | -624.27 Thousand AUD | 0.0% |
| 2023 FY | 1.11 Million AUD | -43.63% |
| 2023 Q2 | 1.74 Million AUD | 0.0% |
| 2022 Q4 | 1.21 Million AUD | 0.0% |
| 2022 Q2 | 760.87 Thousand AUD | 0.0% |
| 2022 FY | 1.98 Million AUD | 29.18% |
| 2021 Q4 | 673.12 Thousand AUD | 0.0% |
| 2021 FY | 1.53 Million AUD | 4485.93% |
| 2021 Q2 | 859.72 Thousand AUD | 0.0% |
| 2020 Q4 | 33.82 Thousand AUD | 0.0% |
| 2020 Q2 | -401.00 AUD | 0.0% |
| 2020 FY | 33.42 Thousand AUD | -31.62% |
| 2019 Q2 | -26.01 Thousand AUD | 0.0% |
| 2019 Q4 | -78.99 Thousand AUD | 0.0% |
| 2019 FY | 48.88 Thousand AUD | -91.27% |
| 2018 FY | 560.12 Thousand AUD | -68.2% |
| 2018 Q4 | -99.55 Thousand AUD | 0.0% |
| 2018 Q2 | 577.15 Thousand AUD | 0.0% |
| 2017 FY | 1.76 Million AUD | 3.91% |
| 2017 Q2 | 1.05 Million AUD | 0.0% |
| 2017 Q4 | 541.16 Thousand AUD | 0.0% |
| 2016 FY | 1.69 Million AUD | 916.11% |
| 2016 Q4 | 1.33 Million AUD | 0.0% |
| 2016 Q2 | 680.66 Thousand AUD | 0.0% |
| 2015 Q3 | 7577.25 AUD | 110.24% |
| 2015 Q2 | -74.01 Thousand AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 FY | -207.68 Thousand AUD | -24.15% |
| 2015 Q4 | -163.97 Thousand AUD | -2264.02% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | -167.28 Thousand AUD | 29.28% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 FY | -236.52 Thousand AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -165.98% |
| Acrux Limited | -1.28 Million AUD | 412.364% |
| Race Oncology Limited | 1.38 Million AUD | -188.561% |
| Biome Australia Limited | 7.66 Million AUD | 47.706% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 161.218% |
| BTC Health Limited | 16.36 Thousand AUD | -24415.599% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 46.191% |
| CSL Limited | 15.28 Billion AUD | 99.974% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 65.144% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 94.864% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 92.127% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 1.44 Million AUD | -177.771% |
| Memphasys Limited | 1606.00 AUD | -249635.492% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 98.045% |
| Noxopharm Limited | -534.81 Thousand AUD | 849.938% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -8.038% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 118.823% |
| Starpharma Holdings Limited | 7.65 Million AUD | 47.62% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -2564.757% |
| Biotron Limited | -40.49 Thousand AUD | 10003.58% |
| Alterity Therapeutics Limited | 3.8 Million AUD | -5.408% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 635.545% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 1430.491% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -38899.922% |
| Patrys Limited | 1.39 Million AUD | -187.682% |
| Orthocell Limited | 3.68 Million AUD | -8.739% |
| Imugene Limited | -5.83 Million AUD | 168.679% |
| PYC Therapeutics Limited | 22.05 Million AUD | 81.818% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 457.086% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -73.203% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 15538.439% |
| Nanollose Limited | -348.95 Thousand AUD | 1249.371% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -230.85% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 4491.158% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -220.456% |
| Nyrada Inc. | -5164.07 AUD | 77766.492% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 98.7% |
| Dimerix Limited | 583.47 Thousand AUD | -587.387% |
| PharmAust Limited | -1641.00 AUD | 244509.019% |
| AnteoTech Limited | 460.39 Thousand AUD | -771.151% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -6959.692% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 1193.539% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 9258.013% |
| Actinogen Medical Limited | 9.93 Million AUD | 59.616% |
| Immuron Limited | 3.33 Million AUD | -20.198% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -54.382% |